Lexicon Pharmaceuticals LXRX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 99.5%0.0pp | 99.4%0.0pp | 99.4%+0.2pp | 99.2%+1.1pp | 98%0.0pp | |
| Operating margin | -34.8%+63.4pp | -98.2%-3.8pp | -94.4%+108pp | -202.6%+366pp | -568.6%+65.6pp | |
| Net margin | -37.5%+63.6pp | -101.1%-4.3pp | -96.8%+110pp | -206.4%+362pp | -568%+76.7pp | |
| EBITDA margin | -34%+63.0pp | -97%-3.5pp | -93.5%+108pp | -201.6%+365pp | -566.7%+65.7pp | |
| Returns | ||||||
| Return on equity | -16%+23.7pp | -39.7%+6.2pp | -45.9%+19.4pp | -65.3%+20.8pp | -86.1%+81.6pp | |
| Return on assets | -9.2%+11.6pp | -20.8%+5.2pp | -26%+14.3pp | -40.3%+9.3pp | -49.6%+26.3pp | |
| Return on invested capital | -13.5%+20.1pp | -33.5%+4.0pp | -37.5%+15.0pp | -52.5%+23.8pp | -76.3%+32.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×-0.1× | 0.3×+0.1× | 0.2×+0.1× | 0.1×0.0× | |
| Inventory turnover | 1.5×+0.4× | 1.1×0.0× | 1.1×-0.2× | 1.3×-0.4× | 1.7×— | |
| Liquidity | ||||||
| Current ratio | 18.8×+13.9× | 4.9×-0.8× | 5.6×+1.5× | 4.2×+1.9× | 2.2×-3.2× | |
| Quick ratio | 18.8×+13.9× | 4.9×-0.8× | 5.6×+1.5× | 4.2×+1.9× | 2.2×-3.2× | |
| Cash ratio | 6.8×+3.7× | 3×-0.6× | 3.6×+2.2× | 1.4×+0.9× | 0.6×-0.9× | |
| Leverage | ||||||
| Debt-to-equity | 0.3×-0.3× | 0.6×0.0× | 0.5×+0.1× | 0.5×-0.4× | 0.9×+0.1× | |
| Debt-to-assets | 0.2×-0.1× | 0.3×0.0× | 0.3×0.0× | 0.3×-0.1× | 0.4×0.0× | |
| Interest coverage | -3.5×+2.3× | -5.9×+1.0× | -6.8×+3.6× | -10.5×+3.6× | -14.1×+1.2× | |
| Per Share | ||||||
| Book value per share | $0.51+71.1% | $0.30-10.4% | $0.33-7.1% | $0.36+4.8% | $0.34-25.5% | |
| Valuation | ||||||
| Market capitalization | $1.02B+273% | $417.91M-14.8% | $490.59M+75.4% | $279.76M+67.9% | $166.58M-37.6% | |
| Enterprise value | $1.01B+219% | $416.82M-12.6% | $476.88M+64.0% | $290.84M+38.5% | $209.95M-31.5% | |
| Price / sales | 14.6×+5.9× | 8.4×+1.5× | 6.9×+2.1× | 4.8×-0.5× | 5.3×-3.3× | |
| Price / book | 5×+2.8× | 3.9×-0.2× | 4.1×+1.9× | 2.2×+0.8× | 1.4×-0.5× | |
| EV / sales | 14.5×+4.4× | 8.4×+1.6× | 6.7×+1.8× | 5×-1.7× | 6.7×-3.1× | |
| Earnings yield | -2.6%+62.5pp | -12%+1.9pp | -14%+29.1pp | -43.1%+63.3pp | -106.4%-31.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Lexicon Pharmaceuticals's profit margins?
- Lexicon Pharmaceuticals (LXRX) runs a 99.5% gross margin and a -34.8% operating margin, with a -37.5% net margin.
- Where do Lexicon Pharmaceuticals's ratios come from?
- Every ratio is computed from Lexicon Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
